AAAAI 2022

Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.

Can individuals who are antibody deficient produce SARS-CoV-2-specific CD4+ and CD8+ T cell responses to vaccination or infection?

How does consumption of processed food by children with atopy and asthma affect the gut microbiota and disease severity?

Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?

Is peanut oral immunotherapy well-tolerated by children in the real world, and does tolerance vary by age or by peanut protein dosage?

APeX -2 trial findings presented at AAAAI 2022 examine the efficacy of berotralstat, in varying doses, as an oral prophylactic for reducing HAE attacks.

Is omalizumab beneficial for children with asthma whose pretreatment serum IgE levels are above the drug manufacturer’s age-approved therapeutic range?

Does pulmonary inflammation resulting from airborne toxicants trigger immune system activation in individuals with asthma and COPD?

Does dupilumab reduce the need for systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma?

Among children with peanut sensitization, is comorbid asthma associated with a higher rate of asthma exacerbations and symptoms?